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Abstract.  The human immunodeficiency virus-1 
(HIV-1) protein Tat binds to cell surface antigens and 
can regulate cellular responses.  Tat has similar im- 
munosuppressive effects as transforming growth fac- 
tor-/3 (TGFfl) and both inhibit lymphocyte proliferation. 
TGFfl is expressed by primary human articular chon- 
drocytes and is their most potent growth factor. The 
present study analyzed the interactions of TGFfl and 
HIV Tat in the regulation of human articular chondro- 
cytes. Synthetic or recombinant full-length Tat (1-86) 
induced chondrocyte proliferation and this was of 
similar magnitude as the response to TGF/L  Tat pep- 
tides that did not contain the RGD motif had similar 
chondrocyte stimulatory activity as full-length Tat. 
Among a  series of Tat peptides, peptide 38-62 which 
contains the basic domain was the only one active, 
suggesting that this region is responsible for the effects 
on chondrocyte proliferation.  Full-length Tat and pep- 
tide 38-62 synergized with TGF~ and induced prolifer- 
ative responses that were greater than those obtained 
with any combination of the known chondrocyte 
growth factors.  Further characterization of the interac- 
tions between Tat and TGF/~ showed that Tat increased 
synthesis and TGFfl activity and TGF/~I  mRNA lev- 
els.  The stimulatory effects of Tat and peptide 38-62 
on chondrocyte proliferation were reduced by neu- 
tralizing  antibodies to TGFfl and by TGF~ antisense 
oligonucleotides. These results identify a virally en- 
coded protein and a  synthetic peptide derived from it 
as novel and potent chondrocyte growth stimuli which 
act at least in part through the induction of TGFfl. 
H 
U~AN  immunodeficiency  virus  (HIV)  ~ Tat  is  a 
virally encoded regulatory protein which stimulates 
HIV gene expression (8) through  binding  to a spe- 
cific binding motif, tar,  in the HIV promoter located in the 
long terminal  repeat (LTR) (4). Tat is encoded by two exons 
and the mature protein contains 86 amino acids.  Domains 
that are functionally important in HIV replication have been 
mapped to the first 72 amino acids encoded by exon 1 and 
include an acidic,  a basic, and a cysteine-rich  domain (9). 
The  acidic  NH2-terminal  domain  has  been  proposed  to 
function as activation  domain;  the region  between amino 
acids 22 and 37 contains 7 cysteine residues that are thought 
to mediate dimer formation  and metal binding;  and a basic 
domain between amino acids 49 and 57 is required for nu- 
clear and nucleolar localization  and binding to tar (5). The 
COOH-terminal 14 amino acids that are encoded by exon 2 
do not appear to be essential in HIV replication  but contain 
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the RGD sequence which is a motif present in extracellular 
matrix proteins and involved with binding  to cell surface 
adhesion receptors (2, 28). Tat requires interaction with cel- 
lular proteins to express its maximal effect on HIV replica- 
tion and several intracellular  proteins that participate  in in- 
teractions  with Tat have been identified (6, 14-18, 20, 23, 31, 
32). Tat can activate the HIV promoter when it is synthesized 
in the same cell that contains  the HIV LTR. In addition,  a 
paracrine mechanism has been suggested that involves syn- 
thesis and secretion of Tat, binding to the cell surface, inter- 
nalization and stimulation of the HIV LTR (12). A paracrine 
function of Tat may also be responsible for the development 
of Kaposi's  sarcoma-like  lesions  in  Tat  transgenic  mice 
which occurred in the absence of intralesional  Tat-express- 
ing  cells (41). Furthermore,  proliferation  of Kaposi's  sar- 
coma cells in vitro was increased  by Tat (7).  In contrast, 
growth-inhibitory  effects have been reported in lymphocytes 
where Tat reduced antigen-induced  T cell responses (38). 
Mechanisms  responsible for these Tat effects are not com- 
pletely characterized.  Binding of Tat to cell surface antigens 
may be nonspecific,  and adsorptive endocytosis has been 
suggested as a mechanism responsible for cellular uptake of 
Tat (10). However, Tat has also been shown to bind to specific 
cell surface receptors such as the otv/$5 integrin  (39) and a 
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acid residues 49-57  (42).  Following active internalization, 
Tat can be  detected in  the  cell nucleus.  It may bind  to 
promoters of cellular genes or possibly increase the DNA 
binding activity of cellular transcription factors and this may 
explain the activation or inhibition of cellular genes by Tat 
(13, 24, 25, 30, 33, 34, 44). 
HIV Tat and the cytokine TGF~ are qualitatively similar 
immunosuppressive  factors  and  both  inhibit  lymphocyte 
proliferation (19, 38).  One possible explanation for the an- 
tiproliferative effects  in  T  ceils  was  that  it  induced the 
production of TGF/3 which is one of the most potent endoge- 
nous growth inhibitors for these cells (29).  TGF/~ as a bi- 
functional regulator of cell function (26), is a potent stimula- 
tor of proliferation in human articular chondrocytes (11, 21). 
Three isoforms of TGF/3 are produced by chondrocytes and 
most other factors that can regulate chondrocyte prolifera- 
tion have effects on the expression of TGF/3 (35, 36).  These 
observations provided the basis for the hypothesis that an in- 
teraction of Tat and TGF/3 should be detectable as growth 
stimulation of Tat in chondrocytes. 
The present study shows that Tat and a peptide containing 
the  basic  domain are  potent chondrocyte growth  factors 
which act in part through the induction of TGF~. 
Materials and Methods 
Chondrocyte Isolation and Culture 
Primary human articular chondrocytes  were isolated as described (37). Car- 
tilage was obtained at autopsy and from the University of California, San 
Diego tissue bank from donors without known history of  joint disease. For 
all experiments reported here, cartilage from the femoral condyles and tibial 
plateaus of the knee joints was used. Care was taken to obtain morphologi- 
cally normal and full thickness cartilage and to avoid inclusion of subchon- 
dral bone. The cartilage surface was gently scraped with a scalpel to remove 
ceils from joint fluid potentially adhering to cartilage.  The  slices were 
washed with DMEM (Whittaker MAB Bioproducts, Walkersville, MD). 
They  were  cut  into  pieces (2-3  mm  3)  and  treated  with  trypsin (10% 
vol/vol) for 15 min in a 37°C waterbath. The tissues were transferred to 
DMEM containing 5 % FBS, penicillin-streptomycin-fungizone  and 2 mg/ 
ml clostridial collagenase type IV (Sigma, St. Louis, MO) and digested for 
3 h on a gyratory shaker until the tissue fragments were dissolved. The ceils 
were washed three times and cultured. 
For studies on TGF~ production, primary chondrocytes were cultured 
in T175 flasks for 24 h after isolation in DMEM 5% FBS. The cells were 
nonadherent at that time point; they were collected, washed two times in 
serum-free media, and plated in 96-well plates for studies on proliferation 
or TGF/~ production. 
Chondrocyte Proliferation Studies 
Cbondrocytes were plated in 96-well flat bottom tissue culture plates in 
DMEM containing 5 % FBS at 5,000 cells per well. Tat and growth factors 
were added and the cells were incubated for 96 h. Proliferation was deter- 
mined by [3H]thymidine uptake during the final 12 h of culture. Cells were 
harvested on an automated cell harvester (Cambridge Tech, Watertown, 
MA) and incorporated radioactivity was quantified by liquid scintillation 
counting. 
Tat Peptides 
Recombinant full-length Tat was obtained from American Biotechnologies 
(Cambridge, MA). Synthetic Tat  1-86 was synthesized using solid phase 
methods that were optimized and adapted to a fully automated peptide syn- 
thesizer (430A;  Applied Biosystems, Inc., Foster City, CA), as described 
in detail elsewhere (3).  Starting with protected aminoacyl pare-resin, N '~ 
tertiary butyloxycarbonyl amino acids with appropriate side chain protect- 
ing groups were added in a stepwise fashion until the entire protected poly- 
peptide chain was formed (3). The product was deprotected using low-high 
HF procedure (3) and dissolved in 6 M guanidine HCI  in 20% mercap- 
toethanol. Care was taken to maintain Tat 1-86 in dithiothreitol (50 raM) 
after each HPLC step and during storage as Tat 1-86 was found to be readily 
oxidized and inactivated. The Tat 1-86 was active in driving transcription 
of HIV LTR CAT constructs. Tat 37-72 was inactive in this assay. 
Synthetic Tat 1-86 was purified by preparative HPLC (Dynamax, Houston, 
TX; 22.5  x  350 mm, C18 column, 300 A pore size, 12/~m packing) and 
Tat 1-86 was further purified by semipreparative reverse.phase HPLC (using 
a Vydac C18 column, 250 x  10 mm, with 5 #M, 300 Apore size packing; 
Separations Group, Hesperia, CA) as previously described (3). The gra- 
dient was 0-60% water-acetonitfile, 0.1% trifluoroacetic acid over 240 rain. 
The "Pat peptides corresponding to the amino acid positions 1-21,  1%42, 
38-62,  55-72,  and 70-86 in the polypeptide sequence were synthesized 
using 4-methyl benzhydryl amine resin (Applied Biosystems Inc.) on a pep- 
tide synthesizer (431A;  Applied Biosystems). 
TGFf3 Assay 
Supernatants were collected from cbondrocyte cultures at the time points 
indicated, centrifuged and frozen at -70°C. Samples were tested for TGF/~ 
activity with and without transient acidification (reduction of the pH in the 
supernatants to pH 1.5 by the addition of 5 M HC1 and neutralization with 
1.4 M NaOH in a 0.7 M HEPES), using the CCL64 assay (36). Titers of 
TGF/3 were expressed in ng/ml based on a standard curve generated by using 
purified porcine TGF~I (R&D Systems, Inc., Minneapolis, MN). This was 
performed with each set of assays. 
CCL64 mink lung epithelial cells which are growth inhibited by TGF/~ 
were allowed to adhere in 96-well flat-bottomed microtiter plates overnight, 
using 100,000  cells per well in 200 #l DMEM containing 5% FBS. After 
24 h the medium was removed and replaced with DMEM containing 1% 
FBS. Standards or conditioned media for TGF/~ detection were added in ap- 
propriate dilutions to a final total volume of 200 #l/well. Cultures were in- 
cubated at 37°C for 24 h and [3H]thymidine was added during the final 4 h 
(1 #Ci/well). Medium was then removed and the plates with the adherent 
cells were frozen at -70°C for 2 h. After thawing, the cells were harvested 
on an automated cell harvester (Cambridge Tech, Watertown, MA) onto 
glass fiber filters and radioactivity was determined by liquid scintillation 
counting. 
Northern Blot Hybridization 
Cbondrocytes were serum starved for 24 h and then stimulated as indicated 
for each experiment. Total  RNA was extracted by the single step guani- 
dinium thiocyanate-phenol-chloroform method.  10-30 #g of total  RNA 
was separated on  1%  Formaldehyde gels, blotted onto nylon filters and 
crosslinked with UV light for 5  rain each side. For analysis with RNA 
probes, the blots were prehybridized in 50%  Formamide, 6x  SSC  (lx 
SSC  =  0.15 M NaC1/0.015 M Na-citrate, pH 7), 0.5% SDS, 0.1% Twecn 
20, 100/zg tRNA/ml for 15 rain at 65°C. The prehybridization mixture was 
replaced with fresh solution containing 106 cpm/ml of probe. Hybridiza- 
tion  was performed overnight at  65°C  and was  followed by washes in 
Ix SSC, 0.1% SDS at room temperature (two times 30 rain) and 0.1x SSC, 
0.1% SDS at 65°C (two times 30 min). Following hybridization with 5  x 
106 clam labeled probe at 650C overnight, the filters were washed in 2x  SSC, 
0.1% SDS at room temperature (four brief washes), 2x SSC, 0.1% SDS at 
65°C (30 min) and two additional washes in 2x  SSC, 0.1% SDS at room 
temperature. The damp filters were exposed to Kodak XAR film with an 
intensifying screen at -70°C for 1 to 5 d. To confirm equal RNA load and 
complete transfer the 18S and 28S bands were visualized with ethidium bro- 
mide on all filters. In addition, RNA load was examined by probing for 
B-actin mRNA. 
Probe Preparation 
TGFf31. The 503-bp PstI-KpnI fragment of TGF/~I cDNA (kindly provided 
by Dr. I.  Braude, Cetus Corp., Emeryville, CA) was subcloned into the 
transcription vector pGEM-4z (Promega Corp., Madison, WI). 
/~-act/n.  Two primers (5'-CGTCGTCGACAACGG-3' and 5'-GACCGT- 
AGCACTACC-3') defining a 216-bp fragment of the cDNA were synthesized, 
with the restriction sites EcoRI and HindIII added at their 5' ends, respec- 
tively. After amplification by PCR the fragment was inserted into pGEM-4z. 
The recombinant plasmids were linearized and transcribed with the ap- 
propriate RNA polymerase (SP6 to T7)  to obtain antisense probe. The 
probes were labeled with [32p]UTP (Amersham Corp., Arlington Heights, 
IL) and separated from unincorporated nucleotides by gel filtration (Centri- 
sep columns; Princeton Separations Inc., Adelphia, NJ). 
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Figure 1. HIV Tat stimulates chondrocyte proliferation.  Chondro- 
cytes were stimulated with the indicated concentrations  of TGF/~ 
(ng/ml) or Tat (#g/ml) and proliferation was measured as [3H]thy- 
midine incorporation  after 96 h. A shows HIV Tat dose response 
and comparison to TGF/5. Results represent mean cpm +  SEM of 
six experiments performed in triplicate. B shows specificity of HIV 
Tat effects. Chondrocytes were stimulated with Tat 1-86  or Tat 1-72. 
An aliquot of Tat 1-86 in solution was oxidized and then added to 
the chondrocyte cultures. 
Growth Factors and Other Reagents 
TGFB1, PDGF-AA, bFGF, IGF-I, and IL-6 were all recombinant  human 
preparations and purchased  from R&D Systems. Neutralizing  rabbit anti- 
body to human TGFB was also obtained from R&D Systems. 
Phosphorothioate  anti-sense oligonucleotides with the sequence 5'-GAA 
GTC AAT GTA CAG-Y corresponding to a region that is conserved among 
the three isoforms of TGFB and the matching sense oligonucleotide  were 
synthesized on a Pharmacia Gene Assembler (Pharmacia Diagnostics Inc., 
Fairfield, NJ) and purified on HPLC. 
Figure  2. Tat synergy with TGF/~  and other chondrocyte growth fac- 
tors. Tat (10/zg/ml) and the different growth factors (concentrations 
shown as ng/ml) were added at initiation of  culture and proliferation 
was measured after 96 h. Results represent mean cpm -1- SEM of 
three experiments performed  in triplicate. 
Results 
HIV Tat Stimulation of Chondrocyte  Proliferation 
HIV-1 Tat was tested in microproliferation assays with pri- 
mary human  articular  chondrocytes.  Synthetic  or  recom- 
binant  preparations of full-length  HIV-1  Tat,  dose depen- 
dently  stimulated chondrocyte DNA  synthesis  (Fig.  1 a). 
Maximal Tat effects were of similar magnitude as the effects 
of TGF~, the most potent growth factor for primary human 
articular chondrocytes. To determine the specificity of these 
effects, Tat was oxidized and this abrogated its chondrocyte 
stimulatory activity (Fig.  1 b). The NH2-terminal 14 amino 
acids of HIV-1 Tat encoded by exon II contain an RGD motif 
which defines interactions with cell surface integrins (2). A 
Tat peptide which contained only the amino acids encoded 
by exon I retained similar chondrocyte growth factor activity 
(Fig. 1 b), indicating that the RGD motif is not involved with 
this Tat effect. Comparison of the effects of HIV-1 Tat and 
TGF~ with other growth factors is shown in Fig. 2. The max- 
imal effects of Tat were of comparable magnitude as those 
of TGF/~ and greater than the effects seen with bFGF, PDGF, 
or IGF-I. The analysis of the interactions between Tat and 
the  other chondrocyte growth factors showed that Tat and 
TGF/~  synergistically  stimulated chondrocyte proliferation 
while the effects of Tat and the other factors were additive 
(Fig.  2).  Tat not only stimulated [3H]thymidine uptake but 
also increased cell numbers to a similar extent as TGF/5 (Ta- 
ble I). 
Analysis of  HIV Tat Domains 
To analyze which domains of Tat are required for the effects 
on chondrocyte proliferation, several peptides (20-22 mers) 
corresponding to different regions of the molecule were syn- 
thesized.  The  Tat  peptide  38-62  stimulated  chondrocyte 
proliferation  (Fig.  3  a)  while  the  other  peptides  had  no 
significant  effect.  In  the  analysis  of its  interactions  with 
Lotz et al. HIV Tat,  TGFI3, and Chondrocyte  Proliferation  367 Table L  TGFI3, Tat and Chondrocyte Replication 
Stimulus 
Media  TGF~  Tat  TGF/~ + Tat 
Experiment  1  68,585  133,243  98,732  193,720 
Experiment 2  86,596  183,021  176,532  275,301 
Primary chondrocytes  were plated at 50,000 cells per well in 6-well plates and 
cultured in media alone (DMEM supplemented with 5% FBS) or stimulated 
with TGF/31 (10 ng/ml), recombinant  Tat 1-86 (10 #g/ml) or both. Cells were 
collected after 5 d, stained with trypan blue and counted. Results represent 
mean values of triplicate determinations. 
TGF/3, Tat 38-62 also showed the synergy that was seen with 
full-length Tat (Fig.  3 b) and induced levels of chondrocyte 
proliferation that exceeded those induced by any other com- 
bination of growth factors tested (not shown). Among the Tat 
Figure 4. Induction of TGF/3 activity by HIV Tat. For the analysis 
of  TGF/3  production, chondrocytes were plated in serum-free media 
and  stimulated  with  Tat  (concentrations  in  tzg/ml)  or  IL-6 (10 
ng/ml),  a known inducer of TGF/3. Conditioned media were col- 
lected after 24 h and tested in the CCL64 assay for active and latent 
TGF/3.  Results  were obtained  from three  chondrocyte cultures. 
Each supernatant was tested  in the CCL64 assay in triplicate. 
peptides tested, Tat 38-62 is highly basic (net charge +7) and 
a recent report suggested that the effects of a similar Tat pep- 
tide were due to this feature (22). Therefore, we tested prota- 
mine,  a  highly basic  polypeptide,  but  it  had  no  effect on 
chondrocyte proliferation  (not shown),  suggesting that the 
effect of peptide  38-62  is  not only a  function of its  basic 
charge. 
Tat Stimulates TGF(3 Expression in Chondrocytes 
Chondrocytes express the TGF01, TGFfl2, and TGF/33 genes 
and produce the corresponding proteins (35, 36). Most of  the 
regulatory  factors that  stimulate  chondrocyte proliferation 
also stimulate TGF/3 production (11). To analyze whether the 
Tat effects occur through TGF/3-dependent mechanisms we 
tested the effect of Tat on TGF/3 production by chondrocytes. 
Tat stimulated the release of increased levels of TGF/~ activ- 
ity (Fig. 4). Furthermore, Tat induced TGFfll mRNA levels 
and showed a strong synergy with TGF/31 which autoinduces 
its mRNA expression (Fig.  5).  Analysis of TGF~I  mRNA 
levels by a  semiquantitative  PCR assay was performed on 
several additional  chondrocyte cultures and showed induc- 
tion of TGF/31  by Tat as  well as the marked  synergy with 
TGF/31  (not shown). 
Figure 3. Effects of HIV Tat peptides on chondrocyte proliferation. 
TGF/3 (ng/ml) and Tat peptides  (#g/ml)  were added at initiation of 
the proliferation studies. A shows effects of peptides alone; B shows 
the combination with TGF/3. Results represent  mean cpm :t: SEM 
of three experiments  performed in triplicate. 
Figure 5.  Regulation  of TGF/~I mRNA 
levels.  Chondrocytes  were  stimulated 
with TGF/31 (10 ng/ml)  or Tat peptide 
38-62 (10 tzg/ml) for 8 h. Total RNA was 
isolated and analyzed for TGF/31 mRNA 
by Northern blotting.  To document the 
amount  of  RNA  loaded,  filters  were 
probed for/3-actin mRNA. Lane 1, media control; lane 2, TGF/3; 
lane 3, Tat; lane 4 TGF/3 plus  Tat. 
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Stimulus 
Media  Tg  TGFB  bFGF 
Cell type 
Primary chondrocytes  439  5,833  6,982  1,432 
Subcult. chondrocytes  678  809  1,372  4,907 
Fibroblasts  902  1,273  891  5,328 
Primary chondrocytes,  subeultured chondrocytes (passage 5), and human skin 
fibroblasts (passage 9) were cultured  in media alone (DMEM  supplemented 
with 5% FBS) or stimulated with recombinant Tat  1-86 (10 #g/ml), TGFISI, 
or  bFGF  (both  at  10  ng/ml).  Proliferation  was determined  after  5  d  by 
[3H]thymidine incorporation  and is shown as mean cpm. 
Figure 6. Involvement of TGF/~ in Tat stimulation of chondrocyte 
proliferation. (A) Chondrocytes were stimulated with Tat 38-62 (10 
gg/ml) and antibodies to TGF/~  or control rabbit IgG (antibody con- 
centrations are shown as ttg/ml) were added at the same time. (B) 
Cells  were  preincubated  with  oligonucleotides  (concentrations 
shown in gM) for 8 h and then stimulated with Tat 38-62 (10 gg/ml). 
Proliferation in all cultures was analyzed 96 h after the addition of 
Tat. TGFB antibodies and oligonucleotides were added only once 
at initiation of culture.  Results represent mean cpm  +  SEM of 
two experiments with different chondrocyte preparations each per- 
formed in triplicate. 
Tat Induced TGFf3 Expression and 
Chondrocyte Proliferation 
To test the role of TGFB in the Tat effects on chondrocytes, 
the cells were cultured in the presence of Tat and an antise- 
rum which neutralizes the biological activity of the TGFB 
isoforms  1-3.  This  antiserum  dose dependently and  spe- 
cifically reduced the stimulatory effects of Tat (Fig.  6 A). 
These effects were observed when antibodies  were added 
only at initiation of culture. These inhibitory effects were re- 
versible. Chondrocytes cultured in the presence of Tat and 
TGF/~ antibody were collected after 4 d and replated. Their 
response to subsequent stimulation with Tat or TGF/~ was 
similar to that of cells that had been precultured in media. 
As an alternative approach to interfering with endogenous 
TGF/~,  antisense  oligonucleotides  corresponding  to  con- 
served regions in the three isoforms of human TGFB were 
synthesized. The antisense oligonucleotide dose dependently 
reduced  the  Tat  stimulation  of chondrocyte proliferation 
while the corresponding sense oligonucleotide had no de- 
tectable effect (Fig. 6 B). These results suggest that the en- 
dogenous production of TGF~ is at least in part responsible 
for Tat-induced chondrocyte proliferation. 
Cell-lineage Specificity of Tat Effects on Proliferation 
Chondrocytes undergo functional and phenotypic changes 
during in vitro subculture,  a process that is referred to as 
dedifferentiation to a fibroblast-like phenotype (1). TGF/~ re- 
sponsiveness with respect to growth stimulation decreases 
during in vitro subculture and TGFB is not the most potent 
stimulator of fibroblast proliferation in monolayer culture 
(11). It was thus tested whether the ability of Tat to stimulate 
chondrocyte proliferation  is  a  function  of cell  type  and 
differentiation. Table II  shows results from a  comparative 
analysis of primary and subcultured chondrocytes and hu- 
man skin fibroblasts. Tat and TGF/~ stimulated proliferation 
of primary  chondrocytes but  not  of subcultured  ceils  or 
fibroblasts. The effects of bFGF are shown as a positive con- 
trol for the stimulation of fibroblast proliferation. Certain 
fibroblast cell lines such as 3T3 show increased proliferation 
in response to TGF/L However, in experiments where TGFfl 
caused a mean 4.7-fold increase in proliferation, Tat did not 
show significant effects alone or in combination with TGFB 
(not shown). 
Discussion 
This study demonstrates that the HIV-1 Tat protein stimulates 
proliferation of normal human articular chondrocytes. This 
is associated with the expression of TGF/~ and the growth 
promoting effect of the Tat protein are at least in part depen- 
dent on the induction of  TGFB. A 24-amino acid peptide con- 
taining the basic domain of the Tat protein induces similar 
levels of chondrocyte proliferation as TGF/3. 
The first suggestion that Tat may be involved with cellular 
responses other than HIV replication was based on observa- 
tions with transgenic mice carrying the Tat gene which de- 
veloped dermal lesions that were similar to Kaposi's sarcoma 
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it was not expressed in the tumor cells, suggesting that the 
Tat-expressing  cells produced factors that stimulated prolif- 
eration of the tumor cells. In a long-term follow-up study the 
Tat transgenic mice also had a higher incidence of  liver cancer 
which may be initiated by growth signals from extrahepatic 
cells expressing the Tat gene (40).  Collectively, these find- 
ings suggest that Tat may directly or indirectly induce the ex- 
pression of growth signals. This could either be a function 
of the Tat protein itself(this notion is supported by the ability 
of  Tat to stimulate proliferation of  Kaposi's sarcoma cells [7] ) 
or to inhibit antigen-induced lymphocyte proliferation (38). 
Alternatively, Tat may induce expression of cellular genes in- 
volved with the regulation of proliferation. 
The Tat protein and TGF3 have similar immunosuppres- 
sive and antiproliferative effects on lymphocytes (19, 38). 
This provided the basis for the present hypothesis that an in- 
teraction between Tat and the bifunctional growth regulator 
TGF3 (26)  should result in growth stimulation in cell sys- 
tems where TGF3 stimulates cell proliferation. Human ar- 
ticular chondrocytes were chosen as a model since TGF3 is 
one of their most potent growth factors (11, 21). 
The results show that Tat induces proliferation of human 
articular chondrocytes. At optimal doses Tat induced similar 
levels of chondrocyte proliferation as TGF3. 
Analysis of different mesenchymal cell types showed that 
the Tat effects on proliferation appear to be cell-type specific. 
It is only seen in primary, differentiated but not in subcul- 
tured, dedifferentiated cells, nor in human skin fibroblasts or 
fibroblast cell lines such as 3T3 which respond to TGF3 with 
increased proliferation. These observations are consistent 
with the growth factor response profile that characterizes 
these three different cell types (11, 21). 
Induction of chondrocyte proliferation is  a  function of 
TGF~ but also of a series of other growth factors. To charac- 
terize the specificity of  the Tat effects we tested a chondrocyte 
response that is specific for TGF3.  Articular chondrocytes 
produce  inorganic pyrophosphate  and  TGF/3  is  the  only 
known stimulator of this response (27). Treatment of human 
chondrocytes with the Tat peptide 37-62 increased inorganic 
pyrophosphate levels  in these cultures to levels that were 
similar to those induced by TGF3 (Rosen, E, and M. Lotz, 
unpublished observations). 
Tat and TGF~ showed strong synergy in the stimulation of 
chondrocytes.  The  level  of chondrocyte proliferation in- 
duced by Tat and TGF3 was greater than that induced by any 
other combination of growth factors tested. This synergy was 
seen  in  measurements of [3H]thymidine  incorporation as 
well as in cell counts. Within 24-48 h TGF3/Tat-treated cul- 
tures were microscopically distinguishable by a greater cell 
density. TGF~ autoinduces the expression of its gene and 
Tat also synergized with TGF3 in increasing mRNA levels. 
Since chondrocytes produce TGF3  (35, 36),  we tested 
whether the Tat effects were mediated through the induction 
of TGF3.  Under conditions where Tat stimulated prolifera- 
tion of these cells it also increased expression of endogenous 
TGF31  mRNA and chondrocytes released similar levels of 
TGF3 in response to IL-6, a known inducer of TGF31  ex- 
pression (35). 
The proliferative effect of  Tat was at least in part dependent 
on  the  induction of TGF3  as  endogenous growth  factor 
TGF/31 as it was reduced by neutralizing antibodies to TGF3 
and by TGF3 antisense oligonucleotides. However,  Tat is 
likely to induce other signals in chondrocytes in addition to 
TGF/~ since synergistic effects could also be observed under 
conditions where optimal amounts of exogenous TGF3 were 
added. 
With the use of different synthetic peptides we identified 
the region in the Tat protein that was responsible for the stim- 
ulation of chondrocytes. A protein that contained only the 
first 72 amino acids encoded by exon I gave similar stimula- 
tion of chondrocytes. This peptide 1-72 lacks the 14 amino 
acids encoded by exon II which contains an RGD sequence 
that is capable of mediating cell adhesion (2). This motif  and 
the NH2-terminal  14 amino acids were not required for the 
Tat effects on chondrocyte proliferation. A series of peptides 
corresponding to the COOH-terminal part of the Tat protein 
showed that peptide 38-62  was the only one active in the 
stimulation of chondrocytes. This peptide contains the basic 
domain of Tat which has been shown to be involved with 
binding of Tat to the cell surface (22). Although the receptor 
responsible for the Tat effects on chondrocytes has not been 
identified it is possible that the av35 integrin may be in- 
volved. This integrin has recently been shown to function as 
a receptor for Tat, and the region in Tat that is responsible 
for binding is contained within the peptide that we have 
shown to have chondrocyte stimulatory activity. In further 
support of  this notion, we have recently shown human articu- 
lar chondrocytes express this integrin (43). It is thus possible 
that Tat acts at the cell surface and induces intracellular sig- 
nals that activate the TGF3 gene and/or promote cell cycle 
progression. Tat may also enter chondrocytes and bind di- 
rectly or in cooperation with host cell factors to the promoter 
of the TGF/31 gene. 
In summary, HIV Tat stimulates chondrocyte prolifera- 
tion. These effects are associated with and in part dependent 
on the induction of TGF~ as endogenous growth factor. The 
basic domain of Tat which has been shown to mediate bind- 
ing to cell surface antigens is also responsible for the effects 
of Tat on chondrocytes. Stimulation of TGF/3 production and 
the resulting increase in chondrocyte proliferation are a cell 
type-specific function of the Tat/TGF3 interaction. 
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